This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Ramipril

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221014

Version

5

Spl Product Data Elements

Ramipril Ramipril RAMIPRIL RAMIPRILAT HYPROMELLOSES CELLULOSE, MICROCRYSTALLINE FERRIC OXIDE YELLOW STARCH, CORN SODIUM STEARYL FUMARATE YELLOW CAPSULE 374 Ramipril Ramipril RAMIPRIL RAMIPRILAT HYPROMELLOSES CELLULOSE, MICROCRYSTALLINE FERRIC OXIDE RED FERRIC OXIDE YELLOW STARCH, CORN SODIUM STEARYL FUMARATE PEACH CAPSULE 375 Ramipril Ramipril RAMIPRIL RAMIPRILAT HYPROMELLOSES CELLULOSE, MICROCRYSTALLINE FERRIC OXIDE RED STARCH, CORN SODIUM STEARYL FUMARATE PINK TO RED CAPSULE 376 Ramipril Ramipril RAMIPRIL RAMIPRILAT HYPROMELLOSES CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM STEARYL FUMARATE WHITE TO OFF-WHITE CAPSULE 377

Application Number

ANDA090697

Brand Name

Ramipril

Generic Name

Ramipril

Product Ndc

65841-701

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-699-05 in bottle of 500 tablets Ramipril Tablets, 1.25 mg Rx only 500 tablets NDC 65841-700-05 in bottle of 500 tablets Ramipril Tablets, 2.5 mg Rx only 500 tablets NDC 65841-701-05 in bottle of 500 tablets Ramipril Tablets, 5 mg Rx only 500 tablets NDC 65841-702- 05 in bottle of 500 tablets Ramipril Tablets, 10 mg Rx only 500 tablets Ramipril Tablets, 1.25 mg Ramipril Tablets, 2.5 mg Ramipril Tablets, 5 mg Ramipril Tablets, 10 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.